Caprock Group LLC Takes Position in Zoetis Inc. $ZTS

Caprock Group LLC bought a new position in Zoetis Inc. (NYSE:ZTS) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 20,840 shares of the company’s stock, valued at approximately $3,271,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC raised its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. NewSquare Capital LLC increased its position in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the last quarter. Financial Consulate Inc. purchased a new stake in Zoetis during the third quarter valued at $39,000. SJS Investment Consulting Inc. raised its stake in Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC bought a new position in Zoetis during the third quarter valued at $42,000. 92.80% of the stock is owned by institutional investors.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Quarterly beat — Zoetis reported adjusted Q4 EPS of $1.48 vs. $1.40 consensus and revenue of about $2.39B, topping estimates; the results show solid margins and modest year-over-year revenue growth. MarketBeat Q4 results
• Positive Sentiment: Raised/strong FY2026 outlook — Management set adjusted EPS guidance of $7.00–$7.10 (above consensus ~6.81) and revenue guidance around $9.8B–$10.0B, pointing to continued strength in companion-animal and international markets. This underpins a constructive longer-term earnings trajectory. Reuters: Zoetis forecasts 2026
• Neutral Sentiment: Investor materials and transcripts available — Full earnings call transcript and slide deck provide more color on regional trends, product mix, and margin assumptions for 2026; these materials will guide how durable the beat and guidance are perceived. Yahoo Finance transcript
• Negative Sentiment: Analyst skepticism on growth trajectory — Several analysts flagged slowing trends in key segments and questioned the sustainability of growth, pressuring sentiment despite the beat and guidance. Benzinga: Analysts question growth
• Negative Sentiment: Outlook nuance and U.S. softness — Coverage notes and commentary highlight that topline growth faces headwinds in the U.S.; investors appear focused on near-term revenue momentum rather than headline EPS/guidance beats. Seeking Alpha: Outlook shows pressure

Zoetis Trading Down 2.4%

Shares of NYSE ZTS opened at $125.58 on Friday. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The company has a market cap of $55.34 billion, a price-to-earnings ratio of 21.14, a PEG ratio of 2.22 and a beta of 0.96. The business’s 50 day moving average price is $124.26 and its 200-day moving average price is $135.72.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the prior year, the company posted $1.40 EPS. Zoetis’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is 35.69%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. HSBC set a $140.00 target price on shares of Zoetis in a research report on Wednesday, December 10th. Stifel Nicolaus decreased their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. Bank of America cut Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a report on Monday, December 15th. JPMorgan Chase & Co. decreased their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Finally, Morgan Stanley set a $160.00 price target on Zoetis in a research report on Thursday, December 18th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.